Comparative Pharmacology
Head-to-head clinical analysis: HICON versus VESICARE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HICON versus VESICARE.
HICON vs VESICARE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Competitive antagonist at muscarinic acetylcholine receptors (M1-M5), with selectivity for M3 receptors over M2. Inhibits bladder detrusor muscle contraction, increasing bladder capacity and reducing urinary urgency.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
5 mg orally once daily; may increase to 10 mg once daily if needed.
None Documented
None Documented
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 45 hours (range 33–57 hours), supporting once-daily dosing.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Approximately 70% of an oral dose is excreted in urine (mainly as metabolites, <15% unchanged) and 25% in feces.
Category C
Category C
Anticholinergic
Anticholinergic